Disease · MONDO_0006663

perinatal asphyxia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. perinatal asphyxia. Diseases, record MONDO_0006663. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006663

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: perinatal asphyxia; Open Targets
Open Targets ID: MONDO_0006663; Open Targets
Other names: Asphyxia - birth, Asphyxia NOS in liveborn infant, Asphyxia, in liveborn infant (disorder), Birth asphyxia (disorder), HIE, Liveborn with birth asphyxia NOS, Liveborn with birth asphyxia NOS (disorder), Neonatal asphyxia, Unspecified severity of birth asphyxia in liveborn infant, asphyxia neonatorum, birth asphyxia, birth depression, fetal asphyxia, foetal asphyxia, hypoxia neonatorum, hypoxic-ischemic encephalopathy, intrapartum asphyxia, perinatal depression, perinatal hypoxia, postnatal asphyxia; Open Targets
Disease Ontology: DOID:11088; Disease Ontology
MeSH: D001238; MeSH
NCI Thesaurus: C116313; NCI Thesaurus
Orphanet: ORPHA:137577; Orphanet
Highest stage of its drugs: Phase 3, for 8 of its 29 drugs, from ClinicalTrials.gov; Open Targets

Drugs29

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EPOETIN BETA	CHEMBL2109092	Protein	Phase 3	ClinicalTrials.gov	7	7	0	Drugs and targets
MAGNESIUM SULFATE	CHEMBL3989857	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
CAFFEINE CITRATE	CHEMBL1200569	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CITICOLINE	CHEMBL1231700	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ALLOPURINOL	CHEMBL1467	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MANNITOL	CHEMBL689	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OXYGEN	CHEMBL1234886	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SILDENAFIL CITRATE	CHEMBL1737	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DARBEPOETIN ALFA	CHEMBL1201566	Protein	Phase 2	ClinicalTrials.gov	4	4	1	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 29

See all 29 drugs

Targets94

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADORA2A	Adenosine A2 receptor	3	Adenosine A2 receptor antagonist; Adenosine receptor antagonist	Phase 3	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	3	Adenosine A2 receptor antagonist; Adenosine receptor antagonist	Phase 3	https://conductscience.org/library/genes/136	Drugs and targets
EPOR	Erythropoietin receptor	3	Erythropoietin receptor agonist	Phase 3	https://conductscience.org/library/genes/2057	Drugs and targets
PDE5A	3',5'-cyclic phosphodiesterase	3	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 5A inhibitor	Phase 3	https://conductscience.org/library/genes/8654	Drugs and targets
ADORA1	Adenosine receptor	2	Adenosine receptor antagonist	Phase 3	https://conductscience.org/library/genes/134	Drugs and targets
ADORA3	Adenosine receptor	2	Adenosine receptor antagonist	Phase 3	https://conductscience.org/library/genes/140	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	2	Adrenergic receptor alpha-2 agonist	Phase 2	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	2	Adrenergic receptor alpha-2 agonist	Phase 2	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	2	Adrenergic receptor alpha-2 agonist	Phase 2	https://conductscience.org/library/genes/152	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor agonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets

1 to 10 of 94

See all 94 targets

Trials38

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04772222	Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial)	Phase 2	50	2026-03-06	Hypoxic-Ischemic Encephalopathy, Pain	DEXMEDETOMIDINE HYDROCHLORIDE, MORPHINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT01862250	Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia	Phase 1/2	13	2018-01-05	Encephalopathy, Hypoxic-Ischemic	CLONIDINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT04043299	Effect of Intrapartum Oxygen Administration on Fetal and Early Neonatal Outcomes	Phase 3	1,108		Fetal Distress, Birth Asphyxia	OXYGEN	Its record names the disease	ClinicalTrials.gov
NCT06855108	Caffeine for Hypoxic Ischemic Encephalopathy	Phase 3	830		Hypoxic Ischemic Encephalopathy (HIE)	CAFFEINE CITRATE	Its record names the disease	ClinicalTrials.gov
NCT03162653	Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome	Phase 3	760		Encephalopathy, Hypoxic-Ischemic, Infant, Newborn, Diseases	ALLOPURINOL, MANNITOL	Its record names the disease	ClinicalTrials.gov
NCT01646619	Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy	Phase 3	300		Severe Hypoxic Ischemic Encephalopathy, Moderate Hypoxic Ischemic Encephalopathy	MAGNESIUM SULFATE	Its record names the disease	ClinicalTrials.gov
NCT04705142	Beneficial Effect of Intravenous Magnesium Sulphate in Term Neonates With Hypoxic Ischemic Encephalopathy(HIE)	Phase 2	200		HIE	MAGNESIUM SULFATE	Its record names the disease	ClinicalTrials.gov
NCT06522581	Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy	Phase 1	200		Hypoxic Ischemic Encephalopathy of Newborn	CITICOLINE	Its record names the disease	ClinicalTrials.gov
NCT05707962	Neuroprotective Efficacy of Postnatal Magnesium Sulphate in Term Infants With Birth Asphyxia	Not applicable	178		Birth Asphyxia	MAGNESIUM SULFATE	Its record names the disease	ClinicalTrials.gov
NCT04432662	Darbepoetin in Neonatal Encephalopathy Trial	Phase 2	150		Neonatal Encephalopathy	DARBEPOETIN ALFA	Its record names the disease	ClinicalTrials.gov

1 to 10 of 38

See all 38 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dexmedetomidine (DMT) vs Morphine: Number of Participants Who Experience Shivering	13 of 25	14 of 23	48	NCT04772222	Trial comparisons
Dexmedetomidine (DMT) vs Morphine: deaths from any cause	0 of 25	1 of 23	48	NCT04772222	Trial comparisons
Dexmedetomidine (DMT) vs Morphine: serious adverse events	1 of 25	1 of 23	48	NCT04772222	Trial comparisons

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34764335	RESULT	1	PubMed
30679288	RESULT	1	PubMed
29561203	RESULT	1	PubMed
29137711	RESULT	1	PubMed
27614933	RESULT	1	PubMed
27126393	RESULT	1	PubMed
24473179	RESULT	1	PubMed
16390366	RESULT	1	PubMed
40850908	DERIVED	1	PubMed
40562301	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006663

GET https://conductscience.org/api/diseases/v1/MONDO_0006663/drugs?page=2

API reference For AI assistants